UBS downgraded AstraZeneca to Sell from Buy with a price target of 10,700 GBp, down from 13,000 GBp, after assuming coverage of the name. The company’s high exposure to U.S. Medicare Part D reform drives UBS’s estimates below consensus in 2025 and 2026, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- AIM ImmunoTech announces open enrollment for Phase 1b/2 study of Ampligen
- Absci appoints Sir Pangalos to its board of directors
- AstraZeneca put volume heavy and directionally bearish
- Compugen to receive $10M milestone payment from AstraZeneca
- Zura Bio names Robert Lisicki as COO, Kiran Nistala as CMO